An individual walks by an indication that reads, “the vaccine is our greatest shot in opposition to COVID-19” on the Higher West Aspect amid the coronavirus pandemic on March 30, 2021 in New York Metropolis.
Noam Galai | Getty Photos
Johnson & Johnson privately requested Covid-19 vaccine rivals Pfizer and Moderna to hitch a research trying into the potential threat of blood clots however the corporations declined, The Wall Street Journal reported Friday, citing individuals aware of the matter.
Executives at Pfizer and Moderna mentioned their vaccines appeared safe and so they did not see the necessity to duplicate the efforts of regulators and corporations already trying into the uncommon blood clot situation, in line with the Journal report.
Solely AstraZeneca, whose vaccine has additionally raised considerations from regulators over blood clots, agreed to hitch the trouble, the Journal mentioned.
CNBC has reached out to the 4 corporations for remark.
On Tuesday, the Meals and Drug Administration and the Facilities for Illness Management and Prevention advised states to temporarily pause using J&J’s vaccine “out of an abundance of warning” after six girls developed a uncommon however doubtlessly life-threatening blood clotting dysfunction that left one useless and one in essential situation.
The ladies developed the situation generally known as cerebral venous sinus thrombosis, or CVST, inside about two weeks of receiving the shot, U.S. well being officers instructed reporters. CVST is a uncommon type of a stroke that occurs when a blood clot types within the mind’s venous sinuses. It will probably finally leak blood into the mind tissues and trigger a hemorrhage.
A CDC panel on Wednesday decided to postpone a decision on using J&J’s vaccine whereas officers examine the circumstances.
— to www.cnbc.com